Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2020 Aug 18

PMID 32801704

Citations 2

Authors

Ke Gong

Yang Dong

Liting Wang

Yi Duan

Jian Yu

Ying Sun

Min Bai

Yourong Duan

Affiliations

Soon will be listed here.

Abstract

Purpose: Platinum/paclitaxel-based chemotherapy is the strategy for ovarian cancer, but chemoresistance, inherent or acquired, occurs and hinders therapy. Therefore, further understanding of the mechanisms of drug resistance and adoption of novel therapeutic strategies are urgently needed.

Methods: In this study, we report that sphingosine-1-phosphate receptor-1 (S1PR1)-mediated chemoresistance for ovarian cancer. Then we developed nanoparticles with a hydrophilic PEG2000 chain and a hydrophobic DSPE and biodegradable CaP (calcium ions and phosphate ions) shell with pH sensitivity as a delivery system (CaP-NPs) to carry BAF312, a selective antagonist of S1PR1 (BAF312@CaP-NPs), to overcome the cisplatin (DDP) resistance of the ovarian cancer cell line SKOV3DR.

Results: We found that S1PR1 affected acquired chemoresistance in ovarian cancer by increasing the phosphorylated-signal transduction and activators of transcription 3 (P-STAT3) level. The mean size and zeta potential of BAF312@CaP-NPs were 116 ± 4.341 nm and -9.67 ± 0.935 mV, respectively. The incorporation efficiency for BAF312 in the CaP-NPs was 76.1%. The small size of the nanoparticles elevated their enrichment in the tumor, and the degradable CaP shell with smart pH sensitivity of the BAF312@CaP-NPs ensured the release of BAF312 in the acidic tumor niche. BAF312@CaP-NPs caused substantial cytotoxicity in DDP-resistant ovarian cancer cells by downregulating S1PR1 and P-STAT3 levels.

Conclusion: We found that BAF312@CaP-NPs act as an effective and selective delivery system for overcoming S1PR1-mediated chemoresistance in ovarian carcinoma by inhibiting S1PR1 and P-STAT3.

Citing Articles

S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.

Chai Y, Xiang H, Ma Y, Feng W, Jiang Z, Zhu Q J Exp Clin Cancer Res. 2024; 43(1):304.

PMID: 39551792 PMC: 11571582. DOI: 10.1186/s13046-024-03230-5.

S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.

Tao Y, Zhu H, Shi Q, Wang C, Hua Y, Hu H Oncogene. 2023; 42(47):3491-3502.

PMID: 37828220 PMC: 10656284. DOI: 10.1038/s41388-023-02853-w.

References

OSullivan C, Schubart A, Mir A, Dev K . The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016; 13:31. PMC: 4746808. DOI: 10.1186/s12974-016-0494-x. View

Takemoto H, Miyata K, Hattori S, Ishii T, Suma T, Uchida S . Acidic pH-responsive siRNA conjugate for reversible carrier stability and accelerated endosomal escape with reduced IFNα-associated immune response. Angew Chem Int Ed Engl. 2013; 52(24):6218-21. DOI: 10.1002/anie.201300178. View

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

Liang J, Nagahashi M, Kim E, Harikumar K, Yamada A, Huang W . Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013; 23(1):107-20. PMC: 3578577. DOI: 10.1016/j.ccr.2012.11.013. View

Levina V, Nolen B, Marrangoni A, Cheng P, Marks J, Szczepanski M . Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res. 2009; 15(8):2647-56. PMC: 2669845. DOI: 10.1158/1078-0432.CCR-08-2024. View

Clamp A, James E, McNeish I, Dean A, Kim J, ODonnell D . Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019; 394(10214):2084-2095. PMC: 6902268. DOI: 10.1016/S0140-6736(19)32259-7. View

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood A . Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14):1557-65. PMC: 4159096. DOI: 10.1001/jama.2011.1456. View

Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway R . Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene. 2011; 31(18):2309-22. PMC: 3245777. DOI: 10.1038/onc.2011.409. View

Kobayashi H, Watanabe R, Choyke P . Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?. Theranostics. 2014; 4(1):81-9. PMC: 3881228. DOI: 10.7150/thno.7193. View

10.

Swisher E, Lin K, Oza A, Scott C, Giordano H, Sun J . Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 18(1):75-87. DOI: 10.1016/S1470-2045(16)30559-9. View

11.

Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A . STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010; 16(12):1421-8. PMC: 3088498. DOI: 10.1038/nm.2250. View

12.

Shu T, Li Y, Wu X, Li B, Liu Z . Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. Cancer Lett. 2017; 411:65-73. DOI: 10.1016/j.canlet.2017.09.048. View

13.

Stilgenbauer M, Jayawardhana A, Datta P, Yue Z, Gray M, Nielsen F . A spermine-conjugated lipophilic Pt(iv) prodrug designed to eliminate cancer stem cells in ovarian cancer. Chem Commun (Camb). 2019; 55(43):6106-6109. DOI: 10.1039/c9cc02081k. View

14.

Wojtaszek J, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K . A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019; 178(1):152-159.e11. PMC: 6644000. DOI: 10.1016/j.cell.2019.05.028. View

15.

Al-Salama Z . Siponimod: First Global Approval. Drugs. 2019; 79(9):1009-1015. DOI: 10.1007/s40265-019-01140-x. View

16.

Dai Y, Ma P, Cheng Z, Kang X, Zhang X, Hou Z . Up-conversion cell imaging and pH-induced thermally controlled drug release from NaYF4/Yb3+/Er3+@hydrogel core-shell hybrid microspheres. ACS Nano. 2012; 6(4):3327-38. DOI: 10.1021/nn300303q. View

17.

Jung J, Shih I, Park J, Gerry E, Kim T, Ayhan A . Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Res. 2016; 76(21):6351-6361. PMC: 7375390. DOI: 10.1158/0008-5472.CAN-16-0980. View

18.

Babu Lankadasari M, Aparna J, Mohammed S, James S, Aoki K, Binu V . Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. Theranostics. 2018; 8(14):3824-3840. PMC: 6071521. DOI: 10.7150/thno.25308. View

19.

McCann G, Naidu S, Rath K, Bid H, Tierney B, Suarez A . Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience. 2015; 1(3):216-28. PMC: 4278289. DOI: 10.18632/oncoscience.26. View

20.

Kreitzburg K, Fehling S, Landen C, Gamblin T, Vance R, Arend R . FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer. Cancer Lett. 2018; 436:75-86. PMC: 6756795. DOI: 10.1016/j.canlet.2018.08.015. View